Humira list price 2026?

The most recent publicly reported list price for Humira (adalimumab) in the United States is roughly $25,000–$30,000 per year (about $2,000–$2,500 per month).

Because Humira’s pricing is set by Abbott/AbbVie and is subject to changes in payer contracts, FDA guidance, and market dynamics, there is no official “2026” price published yet. Industry analysts generally project that the list price will remain in the same ball‑park as the 2023‑2024 range, assuming no major regulatory or competitive shifts.

| Year | Reported List Price (US) |
|------|--------------------------|
| 2022 | $24–$26k per year |
| 2023 | $25–$28k per year |
| 2024 | $25–$30k per year |
| 2025–2026 | Projected $25–$30k per year (subject to change) |

Key points to keep in mind:

- List price vs. net price – The list price is the sticker price. Actual out‑of‑pocket costs for patients are usually far lower because of insurance copay tiers, manufacturer discounts, and pharmacy benefit manager negotiations.
- Regional variations – Prices can differ across countries and even within the U.S. (e.g., Medicare vs. commercial plans).
- Upcoming competition – Biosimilars (e.g., Amjevita, Cyltezo, etc.) are already in the market, which can pressure AbbVie to adjust pricing or offer more aggressive discounts.
- Policy changes – New pricing transparency rules or value‑based contracts could further influence the final patient‑cost.

If you need the most current, precise figure for a particular payer or jurisdiction, the best route is to consult AbbVie’s official pricing schedule or contact their sales representatives, as the published list price may not reflect real‑world negotiated discounts.